← Back to Search

OncoVAX and Surgery for Colon Cancer

Phase 3
Waitlist Available
Research Sponsored by Vaccinogen Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to five years
Awards & highlights

Study Summary

This trial is testing a new cancer vaccine to see if it can prevent cancer recurrence.

Eligible Conditions
  • Colon Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to five years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to five years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease-Free Survival
Secondary outcome measures
Overall Survival
Recurrence-Free Interval

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: OncoVAX and SurgeryExperimental Treatment2 Interventions
Autologous Specific Immunotherapy given intradermally following surgical resection of Stage II colon cancer
Group II: SurgeryActive Control1 Intervention
Surgical resection of Stage II colon cancer
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Surgery
2000
Completed Phase 3
~2550

Find a Location

Who is running the clinical trial?

Vaccinogen IncLead Sponsor
Michael G Hanna, Jr, PhDStudy ChairVaccinogen Inc
Rachel L Hoover, MS, MBAStudy DirectorVaccinogen Inc

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~55 spots leftby Apr 2025